Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Illustration of an elderly woman climbing the stairs cheerfully and an elderly woman who looks distressed

Neuroscience

Annexon Touts ‘Rapid’ and ‘Durable’ Improvements for Targeted Guillain-Barré Therapy

Jefferies analysts predict Annexon’s tanruprubart could be approved by mid-2026.

April 10, 2025

2 min read

Tristan Manalac

Amgen sign at its headquarters in Thousand Oaks, California, USA.

Immunology and inflammation

Amgen’s Uplizna Deepens Response Through 1 Year in Myasthenia Gravis

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be competitors in generalized myasthenia gravis.

April 10, 2025

2 min read

Tristan Manalac

Pictured: Entrance to the U.S. Department of Healt

Government

Appeals Court Stops Rehiring of Fired Federal Workers, Including From HHS

The Fourth Circuit’s ruling follows a Supreme Court verdict that also allowed the Trump administration to move forward with its mass layoffs at federal agencies.

April 10, 2025

2 min read

Tristan Manalac

Photo of Jersey City skyline viewed from a boat sailing the Upper Bay

Business

New Jersey’s Life Sciences Scene Continues Expanding Beyond Big Pharma

Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more small and midsize life sciences businesses. Choose New Jersey, Grace Therapeutics and Onyx Equities executives discuss the state’s life sciences scene.

April 10, 2025

6 min read

Angela Gabriel

Lifebuoy for help and Support to survive Concept. Hands of a businessman who receives and Digital Graphic design on Blue background. copy space- 3d rendering

Tariffs

‘Put On Your Life Vest’: Pharma Tariffs Are Coming

As the industry awaits official word from the administration on how the tariffs will hit, analysts go over the possibilities with one certainty: there will be increased costs for medicines.

April 9, 2025

5 min read

Annalee Armstrong

Stack of coins balancing on seesaw over a bottle of pills.

Tariffs

Trump Says ‘Major’ Pharma Tariffs Coming ‘Very Shortly’ After Sparing Industry on Liberation Day

Analysts suggested that the tariffs will have little effect on reshoring manufacturing and will likely decrease patient drug access and increase costs.

April 9, 2025

2 min read

Tristan Manalac

China

Amid Trade Tensions, Commission Warns China is ‘Dangerously Close’ to Overtaking US Biotech

The National Security Commission on Emerging Biotechnology recommends at least a $15 billion investment into biotech over the next five years.

April 9, 2025

2 min read

Tristan Manalac

Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto

Legal

BMS Scores Two on Tuesday With Colorectal Cancer Approval, Court Win

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action complaint over the blood cancer drug Pomalyst.

April 9, 2025

2 min read

Tristan Manalac